CDK8 and neoplasm: The enhanced in vivo efficacy may be attributable to the effects of CDK8/19i on the tumor microenvironment (TME) caused by suppressing tumor-promoting paracrine activities of stromal fibroblasts and stimulating the antitumor activity of NK cells [35,45], as seen in other models.